Maxim Group analyst Jason McCarthy, believes that the concern for a CAR-T cell, whether from Juno Therapeutics (NASDAQ: JUNO) or ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE